Glenmark's marketing of a couple of diabetes generics in the United States continues to fluctuate like a yo-yo on a string. Now the India drugmaker can return the drugs to market until April 28.
Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.
U.S.-based Orgenesis has been contracting for the sophisticated manufacturing capabilities of MaSTherCell as it moves to clinical trials with its process to reprogram human liver cells in people with Type 1 diabetes into insulin-producing cells. Now it will own them.
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression.
A group of researchers at Cornell says it engineered a human probiotic that also had a similar effect in controlling blood glucose levels in rat models for the disease. And a biotech has already snagged the license on this work as they set the stage to try it in humans.
A transatlantic team of researchers says that they have identified a new pathway in the brain that plays a critical role in signaling hypoglycemia. And they add that it's a solid target for drug researchers working in the blockbuster field.
Shanghai's Hua Medicine hauled in a $25 million B round to advance its work on a new treatment for diabetes, bringing in investors from the U.S. and China as it moves toward late-stage development.
Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.
Roche's Lucentis may now have a bigger jump on Eylea in diabetic retinopathy. The Swiss drugmaker's Genentech unit won the FDA's "breakthrough" designation for that indication on Monday. And Lucentis was already on the FDA's priority review track, with a decision date in February.
Brown fat is once again providing clues in how to treat metabolic disorders like diabetes. A group of investigators at the University of Michigan followed up on earlier studies that have examined the role of brown fat in burning calories. Their work led them to NRG4, a hormone secreted by brown fat that may play a role as a messenger with the liver in regulating the conversion of sugar into fat, according to the university.